Thermo Fisher Scientific (NYSE:TMO) Stock Sees Unusually High Put Option Buying

Thermo Fisher Scientific Inc. (NYSE:TMO) saw some unusual options trading on Wednesday. Stock traders purchased 4,906 put options on the company. This is an increase of 52% compared to the average daily volume of 3,229 put options.

Insider Activity

In other Thermo Fisher Scientific news, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. Bank of New York Mellon Corp purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $1,974,561,000. Bank of America Corp DE bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,952,930,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after purchasing an additional 22,827 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $1,122,351,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 1.9%

Shares of NYSE:TMO traded up $13.00 during trading on Wednesday, reaching $700.37. 1,499,509 shares of the stock were exchanged, compared to its average volume of 2,257,862. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $704.00. The stock has a fifty day moving average of $640.60 and a two-hundred day moving average of $551.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $258.96 billion, a price-to-earnings ratio of 37.75, a price-to-earnings-growth ratio of 2.83 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $5.79 EPS. Research analysts anticipate that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. TD Cowen increased their price target on Thermo Fisher Scientific from $675.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada set a $740.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, October 15th. Scotiabank started coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Finally, HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $654.05.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9% year over year and above the approximately $11.95 billion consensus estimate. Adjusted EPS rose 15% to $6.68, beating expectations of $6.40, while organic revenue growth reached 6%. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Improved margins and double-digit adjusted profit growth suggest operating leverage and resilient demand across the company’s life-science tools and services businesses. The quarter also extended Thermo Fisher’s record of earnings beats. Thermo Fisher posts higher third-quarter revenue and earnings as margins improve
• Neutral Sentiment: The broader bioprocessing market is expected to expand as biologics manufacturing, vaccine production, outsourcing, artificial intelligence and single-use systems gain adoption. This provides a favorable industry backdrop for Thermo Fisher, though the market reports are not company-specific financial guidance. Global Bioprocessing Reagent Market Report 2026
• Negative Sentiment: Despite the earnings and revenue beats, shares initially fell in premarket trading. The decline likely reflected high investor expectations following a strong run-up, as well as potential concerns about whether the results and outlook were strong enough to justify TMO’s premium valuation. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Investors purchased 4,906 put options, 52% above typical put volume of 3,229 contracts. The activity signals increased near-term hedging or bearish speculation, although options flow alone does not establish a longer-term negative outlook.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.